GH Research (NASDAQ:GHRS) Trading 4.1% Higher - Here's Why

GH Research PLC (NASDAQ:GHRS - Get Free Report) shares shot up 4.1% during trading on Wednesday . The stock traded as high as $12.11 and last traded at $12.18. 41,792 shares were traded during trading, a decline of 77% from the average session volume of 180,415 shares. The stock had previously closed at $11.70.

Wall Street Analyst Weigh In

GHRS has been the subject of a number of research reports. Cantor Fitzgerald raised shares of GH Research to a "strong-buy" rating in a research note on Tuesday, May 13th. Stifel Nicolaus lifted their target price on GH Research from $18.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of GH Research in a research note on Friday, May 9th. Wall Street Zen lowered shares of GH Research from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Finally, Guggenheim cut their price target on shares of GH Research from $32.00 to $29.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $30.43.

GH Research Trading Down 0.8%

The business has a fifty day moving average price of $10.31 and a two-hundred day moving average price of $10.15. The firm has a market capitalization of $623.30 million, a PE ratio of -15.16 and a beta of 0.86.

GH Research (NASDAQ:GHRS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.61) by $0.42. On average, equities analysts forecast that GH Research PLC will post -0.8 earnings per share for the current fiscal year.

Institutional Trading of GH Research

A number of hedge funds and other institutional investors have recently bought and sold shares of GHRS. BNP Paribas Financial Markets purchased a new stake in shares of GH Research in the 4th quarter valued at about $44,000. Palumbo Wealth Management LLC purchased a new stake in GH Research during the first quarter worth about $142,000. XTX Topco Ltd acquired a new stake in GH Research in the first quarter valued at $169,000. Two Sigma Investments LP acquired a new position in GH Research during the fourth quarter worth about $117,000. Finally, Millennium Management LLC acquired a new stake in GH Research during the 4th quarter valued at $145,000. 56.90% of the stock is currently owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).